Market revenue in 2024 | USD 21,137.4 million |
Market revenue in 2035 | USD 62,629.0 million |
Growth rate | 9.7% (CAGR from 2025 to 2035) |
Largest segment | Ozempic (semaglutide) |
Fastest growing segment | Ozempic (semaglutide) |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2035 |
Quantitative units | Revenue in USD million |
Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 71.15% in 2024. Horizon Databook has segmented the North America semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
The North America semaglutide market holds a leading position in 2024, accounting for 74.35% of the global share, driven by high obesity and diabetes prevalence, strong healthcare infrastructure, and widespread adoption of GLP-1 receptor agonists like Ozempic and Wegovy.
The region benefits from favorable reimbursement policies, increasing weight management awareness, and rising prescriptions for off-label use. The U.S. dominates due to robust pharmaceutical regulations, active patient engagement, and significant investments in obesity therapeutics.
Additionally, market growth is fueled by ongoing clinical advancements, including oral semaglutide formulations. With continuous regulatory oversight and expanding treatment accessibility, North America remains the largest market for semaglutide-based therapies.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America semaglutide market , including forecasts for subscribers. This continent databook contains high-level insights into North America semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
No related statistics found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account